Key points
- Core ARR and expansion revenue increased by 5.5% to $6.674m
- Total Operating Expenses including R&D reduced by $880K to $8.577m
- EBITDA improved 28% from ($760K) to ($545K)
- Profit before Tax improves 13% from ($866K) to ($758K)
- Technology upgrade to SaaS platforms completed
Full summary
Global Health Limited (ASX: GLH) has reported its full-year results for FY2026, reflecting a focus on revenue quality and margin improvement. Core ARR Subscription Revenue grew 8%, and together with expansion revenue, totaled $6.674m, representing 93% of Total Customer Revenue. Lower-margin professional services revenue was down $530K to $463K. Total Operating Expenses including R&D reduced by $880K (9%) to $8.577m. EBITDA improved 28% from a loss of $760K in FY25 to a loss of $545K in FY26. Profit before Tax improved 13% from ($866K) to ($758K). The Company completed the major investment in upgrading its on-premises provider applications to MasterCare Plus, a multi-tenanted, configurable SaaS business.
Outlook
The focus for FY2027 will be on growing revenue (ARR) and improving margins, with additional sales resources and potential sales channel partners.